onward! onl hits milestones and achieves tranche 2 funding OF $46.9 MILLION SERIES B

Congratulations to the ONL team on reaching significant milestones in 2021. This tranche of funding will further expand three programs and move ONL1204 closer to the clinic. 
​
We'd like to thank and congratulate Mr. Esposito, Dr. Zacks, and the ONL team for this accomplishment. The ExSight team is looking forward to the next steps in the journey, advancing these programs into Phase 2 of the US regulatory process. 

CEO, David Esposito commented, "We are excited to have reached our critical milestones, advancing ONL1204 into open-angle glaucoma and GA associated with dry AMD. With the support of our investors, we are grateful for the opportunity to further expand our development program into two chronic indications, each with significant unmet medical needs, while also working to close out our Phase 1 study in retinal detachment." ​

Read the full press release here.

Bonus: Dr. Rahhal's Podcast with the ONL CEO - From West Point to ONL's C-Suite